Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine
Autore:
Pesco-Koplowitz, L; Hassell, A; Lee, P; Zhou, HH; Hall, N; Wiesinger, B; Mechlinski, W; Grover, M; Hunt, T; Smith, R; Travers, S;
Indirizzi:
Janssen Res Fdn, Clin Pharmacol Nonclin Dev, Titusville, NJ 08560 USA Janssen Res Fdn Titusville NJ USA 08560 lin Dev, Titusville, NJ 08560 USA Novartis Pharmaceut Co, Summit, NJ USA Novartis Pharmaceut Co Summit NJ USA artis Pharmaceut Co, Summit, NJ USA PPD Pharmaco, Austin, TX USA PPD Pharmaco Austin TX USAPPD Pharmaco, Austin, TX USA Novum Inc, Pittsburgh, PA USA Novum Inc Pittsburgh PA USANovum Inc, Pittsburgh, PA USA
Titolo Testata:
JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 1, volume: 39, anno: 1999,
pagine: 76 - 85
SICI:
0091-2700(199901)39:1<76:LOEOEA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
TORSADES-DE-POINTES; TOPICAL LEVOCABASTINE; VENTRICULAR-TACHYCARDIA; TERFENADINE METABOLISM; ASTEMIZOLE OVERDOSE; ITRACONAZOLE; CONSEQUENCES; ASSOCIATION; ANTAGONIST; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Pesco-Koplowitz, L Janssen Res Fdn, Clin Pharmacol Nonclin Dev, 1125 Trenton Harbourton Rd,POB Janssen Res Fdn 1125 Trenton Harbourton Rd,POB 200 Titusville NJ USA 08560
Citazione:
L. Pesco-Koplowitz et al., "Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine", J CLIN PHAR, 39(1), 1999, pp. 76-85

Abstract

The single-dose effects of the cytochrome P-450 inhibitors erythromycin and ketoconazole on the steady-state pharmacokinetics and electrocardiographic repolarization pharmacodynamics of intranasal levocabastine, a potent andselective H-1-receptor antagonist were evaluated in healthy young male subjects. Two randomized, open-label, placebo-controlled; two-way crossover studies were performed Levocabastine nasal spray was administered as two sprays per nostril (0.05 mg/spray) twice daily (For a total daily dose of 0.4 mg)for 6 days. On Day 7, a single dose of 0.2 mg was administered followed immediately by a single dose of either oral placebo, erythromycin 333 mg, orketoconazole 200 mg. In all treatment groups, levocabastine was rapidly absorbed, with peak plasma concentrations reached at approximately 3 hours inthe erythromycin study and 2.8 hours in the ketoconazole study. The mean terminal half-life was approximately 45 and 44 hours, respectively. In both studies, mean steady-state plasma concentrations and pharmacokinetics of levocabastine following the single doses of erythromycin or ketoconazole werenot significantly different from corresponding values seen with the concomitant administration of the placebo. No clinically significant mean changesfrom baseline in QT or QT(c) (QT corrected for heart rate) intervals occurred in any of the treatment groups, and none of the subjects in either study experienced abnormally prolonged QT(c) intervals. Intranasal levocabastine was well tolerated, with no difference in the incidence of adverse eventsbetween treatment groups in either study; adverse events were generally mild in severity Since levocabastine undergoes only minimal hepatic metabolism and is not a substrate for or an inhibitor of cytochrome P-450, the likelihood of systemic drug interactions with drugs affecting the cytochrome P-450 system is minimal. Journal of Clinical pharmacology, 1999;39:76-85 (C) 1999 the American College of Clinical pharmacology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/06/18 alle ore 17:19:19